{"success":true,"data":{"pressRelease":{"id":"171324","rtpr_id":"nGNX9RFPqN-20261016","ticker":"BBNX","exchange":"NASDAQ","all_tickers":["BBNX"],"title":"BBNX Securities Announcement: Beta Bionics Investors with Losses have Rights in Pending Securities Fraud Class Action – BFA Law Reminds Shareholders of Upcoming Deadline","author":"Globe Newswire","published_at":"2026-10-16T10:18:00.609Z","article_body":"NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm\nBleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=jXe67LpGYCRMGfUWjZYaFDYbCWxyhBLBfdCYd-T1NbGJloqfLM3ASDHC5O1i7WjKxUXjC5i_EgbzB-pBio_HR_2T4XGVE6tYt9SNZid_4bTymu0lpWlD9tcwgvI2fB7p7sOHwu11GpYOhcyUB_uLc-be1KkDRl_zdMRrfngzaww=)\nannounces that a class action lawsuit has been filed against Beta Bionics,\nInc. (NASDAQ:BBNX) and certain of the company’s senior executives for\nsecurities fraud after its significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in Beta Bionics, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit.\n\nKey Details of the Beta Bionics ($BBNX) Class Action:\n* Lead Plaintiff Deadline: November 3, 2026\n* Alleged Misconduct: Securities fraud alleging that Beta Bionics misled\ninvestors about the safety of its iLet medical device\n* Largest Alleged Stock Drop: January 8–9, 2026 – 37% Stock Drop\n* Court: U.S. District Court for the Central District of California\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit) to discuss\nyour rights\nInvestors have until November 3, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nBeta Bionics common stock. The class action is pending in the U.S. District\nCourt for the Central District of California. It is captioned Holtzman v.\nBeta Bionics, Inc., No. 26-cv-9999.\n\nWhy is Beta Bionics Being Sued for Securities Fraud?\n\nBeta Bionics is a commercial-stage medical device company that offers an\nautomated insulin delivery system for the treatment of diabetes, known as the\niLet Bionic Pancreas insulin pump (“iLet”), launched in 2023. The iLet is\nan insulin delivery system for treatment of diabetes types 1 and 2 that\npurports to be fully autonomous, determining 100% of insulin doses without\nmanual carbohydrate counting or correction calculations by the user.\n\nThe complaint alleges that Beta Bionics falsely touted “the superior\nclinical outcomes of the iLet” and that healthcare professionals “are\nseeing good results from their patients and becoming more comfortable\nprescribing the iLet.”\n\nHowever, the complaint alleges that in June 2025, the FDA issued Beta Bionics\na Form 483 detailing more than 18,000 unreported complaints from iLet users\nsince its launch. The complaints concerned, allegedly, cases of\nlife-threatening hypoglycemia due to iLet’s aggressive insulin dosing\nalgorithm which Beta Biotics failed to investigate or take corrective actions\nto address.\n\nWhy did Beta Bionics’ Stock Drop?\n\nOn January 8, 2026, after hours, Beta Bionics announced that a key business\nmetric—the number of new patients starting iLet treatment, or “new patient\nstarts”—had missed analyst estimates by nearly 10%. As alleged, this news\ncaused the price of Beta Bionics stock to decline by $11.85 per share, or 37%,\nfrom a closing price of $31.99 per share on January 8, 2026 to a closing price\nof $20.14 per share on January 9, 2026.\n\nThen, on February 24, 2026, the FDA publicly released a 10-page warning\nletter, which it had previously sent to Beta Bionics, stating that the Company\nfailed to report instances of hypoglycemia caused by iLet malfunctions. As\nalleged, this news caused the price of Beta Bionics stock to decline by $0.66,\nor 4.9%, from a closing price of $13.55 per share on February 24, 2026 to a\nclosing price of $12.89 per share on February 25, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nWhat Can You Do?\n\nIf you invested in Beta Bionics, you may have legal options and are encouraged\nto submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360, and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.”  One testimonial described the firm\nas “nimble and entrepreneurial,” with a “relentless focus on adding\nvalue for clients.”\n\nBFA’s notable successes include a recovery of over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9RFPqN-20261016","title":"BBNX Securities Announcement: Beta Bionics Investors with Losses have Rights in Pending Securities Fraud Class Action – BFA Law Reminds Shareholders of Upcoming Deadline","author":"Globe Newswire","ticker":"BBNX","created":"2026-10-16T10:18:00.609Z","tickers":["BBNX"],"exchange":"NASDAQ","article_body":"NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm\nBleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=jXe67LpGYCRMGfUWjZYaFDYbCWxyhBLBfdCYd-T1NbGJloqfLM3ASDHC5O1i7WjKxUXjC5i_EgbzB-pBio_HR_2T4XGVE6tYt9SNZid_4bTymu0lpWlD9tcwgvI2fB7p7sOHwu11GpYOhcyUB_uLc-be1KkDRl_zdMRrfngzaww=)\nannounces that a class action lawsuit has been filed against Beta Bionics,\nInc. (NASDAQ:BBNX) and certain of the company’s senior executives for\nsecurities fraud after its significant stock drop resulting from potential\nviolations of the federal securities laws.\n\nIf you invested in Beta Bionics, you are encouraged to obtain additional\ninformation by visiting:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit.\n\nKey Details of the Beta Bionics ($BBNX) Class Action:\n* Lead Plaintiff Deadline: November 3, 2026\n* Alleged Misconduct: Securities fraud alleging that Beta Bionics misled\ninvestors about the safety of its iLet medical device\n* Largest Alleged Stock Drop: January 8–9, 2026 – 37% Stock Drop\n* Court: U.S. District Court for the Central District of California\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit) to discuss\nyour rights\nInvestors have until November 3, 2026 to ask the Court to be appointed to lead\nthe case. The complaint asserts securities fraud claims under Sections 10(b)\nand 20(a) of the Securities Exchange Act of 1934 on behalf of investors in\nBeta Bionics common stock. The class action is pending in the U.S. District\nCourt for the Central District of California. It is captioned Holtzman v.\nBeta Bionics, Inc., No. 26-cv-9999.\n\nWhy is Beta Bionics Being Sued for Securities Fraud?\n\nBeta Bionics is a commercial-stage medical device company that offers an\nautomated insulin delivery system for the treatment of diabetes, known as the\niLet Bionic Pancreas insulin pump (“iLet”), launched in 2023. The iLet is\nan insulin delivery system for treatment of diabetes types 1 and 2 that\npurports to be fully autonomous, determining 100% of insulin doses without\nmanual carbohydrate counting or correction calculations by the user.\n\nThe complaint alleges that Beta Bionics falsely touted “the superior\nclinical outcomes of the iLet” and that healthcare professionals “are\nseeing good results from their patients and becoming more comfortable\nprescribing the iLet.”\n\nHowever, the complaint alleges that in June 2025, the FDA issued Beta Bionics\na Form 483 detailing more than 18,000 unreported complaints from iLet users\nsince its launch. The complaints concerned, allegedly, cases of\nlife-threatening hypoglycemia due to iLet’s aggressive insulin dosing\nalgorithm which Beta Biotics failed to investigate or take corrective actions\nto address.\n\nWhy did Beta Bionics’ Stock Drop?\n\nOn January 8, 2026, after hours, Beta Bionics announced that a key business\nmetric—the number of new patients starting iLet treatment, or “new patient\nstarts”—had missed analyst estimates by nearly 10%. As alleged, this news\ncaused the price of Beta Bionics stock to decline by $11.85 per share, or 37%,\nfrom a closing price of $31.99 per share on January 8, 2026 to a closing price\nof $20.14 per share on January 9, 2026.\n\nThen, on February 24, 2026, the FDA publicly released a 10-page warning\nletter, which it had previously sent to Beta Bionics, stating that the Company\nfailed to report instances of hypoglycemia caused by iLet malfunctions. As\nalleged, this news caused the price of Beta Bionics stock to decline by $0.66,\nor 4.9%, from a closing price of $13.55 per share on February 24, 2026 to a\nclosing price of $12.89 per share on February 25, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nWhat Can You Do?\n\nIf you invested in Beta Bionics, you may have legal options and are encouraged\nto submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nOr contact:\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360, and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.”  One testimonial described the firm\nas “nimble and entrepreneurial,” with a “relentless focus on adding\nvalue for clients.”\n\nBFA’s notable successes include a recovery of over $900 million in value\nfrom Tesla, Inc.'s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-16T10:18:00.659062158Z","server_sent_at_ms":1792145880659},"received_at":"2026-10-16T10:18:00.790Z","source_url":null},"analysis":{"id":"159494","press_release_id":"171324","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["pending securities fraud class action alleging concealment of 18,000+ unreported iLet adverse-event complaints","FDA warning letter publicly released Feb 24, 2026 regarding unreported hypoglycemia incidents"],"eventType":"legal_litigation","narrative":"Plaintiff firm Bleichmar Fonti & Auld announced a pending securities fraud class action against Beta Bionics and certain senior executives, with a November 3, 2026 lead plaintiff deadline.\n\nThe suit alleges the company misled investors about iLet safety — including a June 2025 FDA Form 483 citing 18,000+ unreported user complaints of hypoglycemia — after new patient starts missed estimates and shares fell 37% on January 8-9, 2026.\n\nThis is a law-firm solicitation notice, not an issuer disclosure; the underlying FDA and stock-drop events were previously public. Treat as low-signal noise for BBNX.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress, but note the FDA warning-letter overhang on BBNX."},"keyFigures":{"customDimensions":{"stock_drop_percent":"37%","unreported_complaints":"more than 18,000","lead_plaintiff_deadline":"November 3, 2026"}},"namedEntities":{"people":[{"name":"Adam McCall","role":"BFA Law contact"}],"products":["iLet Bionic Pancreas insulin pump"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"target of class action"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulator referenced in allegations"},{"name":"Tesla, Inc.","relationship":"prior law-firm recovery referenced"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"prior law-firm recovery referenced"}],"dollarAmounts":[{"amount":"$11.85 per share","context":"Jan 8-9, 2026 stock decline"},{"amount":"$31.99 per share","context":"closing price Jan 8, 2026"},{"amount":"$20.14 per share","context":"closing price Jan 9, 2026"},{"amount":"$900 million","context":"prior BFA recovery from Tesla's board"},{"amount":"$420 million","context":"prior BFA recovery from Teva"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Bleichmar Fonti & Auld LLP seeking lead plaintiffs; no new issuer disclosure, no certified class, and no settlement. Underlying allegations (FDA Form 483, warning letter, 37% January stock drop) are already public."},"tickerRelevance":{"others":[],"primary":"BBNX"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Plaintiff firm Bleichmar Fonti & Auld announced a pending securities fraud class action against Beta Bionics and certain senior executives, with a November 3, 2026 lead plaintiff deadline.\n\nThe suit alleges the company misled investors about iLet safety — including a June 2025 FDA Form 483 citing 18,000+ unreported user complaints of hypoglycemia — after new patient starts missed estimates and shares fell 37% on January 8-9, 2026.\n\nThis is a law-firm solicitation notice, not an issuer disclosure; the underlying FDA and stock-drop events were previously public. Treat as low-signal noise for BBNX.","key_figures":{"customDimensions":{"stock_drop_percent":"37%","unreported_complaints":"more than 18,000","lead_plaintiff_deadline":"November 3, 2026"}},"named_entities":{"people":[{"name":"Adam McCall","role":"BFA Law contact"}],"products":["iLet Bionic Pancreas insulin pump"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"target of class action"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulator referenced in allegations"},{"name":"Tesla, Inc.","relationship":"prior law-firm recovery referenced"},{"name":"Teva Pharmaceutical Ind. Ltd.","relationship":"prior law-firm recovery referenced"}],"dollarAmounts":[{"amount":"$11.85 per share","context":"Jan 8-9, 2026 stock decline"},{"amount":"$31.99 per share","context":"closing price Jan 8, 2026"},{"amount":"$20.14 per share","context":"closing price Jan 9, 2026"},{"amount":"$900 million","context":"prior BFA recovery from Tesla's board"},{"amount":"$420 million","context":"prior BFA recovery from Teva"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-16T10:18:12.093Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":5834,"modelName":"glm-5.3-flashx"}}